NASDAQ · IKNA
Healthcare · Biotechnology
$17.16
Up+$15.79 (+1152.55%)
Updated Aug 22, 2026, 6:56 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IKNA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning IKNA.
IKNA research
Company profile and research snapshot.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 25, 2025 | Wedbush | Neutral | — |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | — |
| May 29, 2024 | Wedbush | Neutral | — |
| May 29, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 25, 2025
Inmagene Biopharmaceuticals completed a merger with Ikena Oncology, creating ImageneBio, Inc., and raised $75 million in a private placement. The combined company will continue developing IMG-007, a non-depleting anti-OX40 monoclonal antibody for atopic dermatitis, with a Phase 2b trial expected to have topline results in Q4 2026.
Benzinga · Jul 15, 2025
Ikena Oncology shareholders approved a merger with Inmagene Biopharmaceuticals, with plans to rename the company ImageneBio and trade under ticker 'IMA'. The merger will be accompanied by a 1-for-12 reverse stock split, reducing outstanding shares from 48.2 million to approximately 4 million.
Benzinga · Dec 23, 2024
Ikena Oncology and Inmagene Biopharmaceuticals have announced a merger agreement, with Inmagene's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, as the focus of the combined company. The transaction is expected to result in $175 million to support further development of IMG-007.
Benzinga · May 29, 2024
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for the company and its development pipeline. The company said that based on a review of clinical data to date, available resources, and strategic priorities, the company decided to discontinue the development of IK-930. The IK-930 Phase 1 program will begin winding down activities; treatment will continue for enrolled patients who have derived benefits. The company will seek strategic options for the program, including potential partners for developing IK-930 in combination with other targeted agents. In November 2023, Ikena shared initial data from twenty-six patients treated in ...Full story available on Benzinga.com
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IKNA.
No results
No recent SID articles mention IKNA.
